Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial

详细信息	查看全文 | 推荐本文 |

• 作者：Olga Pleguezuelos ; Stuart Robinson ; Gregory A. Stoloff ; Wilson Caparró ; s-Wanderley ; ^{wilson.wanderley@seekacure.com}
• 关键词：Influenza ; Vaccine ; Clinical trial ; Synthetic polypeptides ; Safety ; Cellular immunity ; Antibody immunity
• 刊名：Vaccine
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：29 June, 2012
• 卷：30
• 期：31
• 页码：4655-4660
• 文件大小：389 K

摘要

Objectives

Current Influenza vaccines elicit antibody mediated prophylactic immunity targeted to viral capsid antigens. Despite their global use these vaccines must be administered yearly to the population, cannot be manufactured until the circulating viral strain(s) have been identified and have limited efficacy. A need remains for Influenza vaccines addressing these issues and here we report the results of a Phase Ib trial of a novel synthetic Influenza vaccine (FLU-v) targeting T cell responses to NP, M1 and M2.

Methods

Forty-eight healthy males aged 18-40 were recruited for this single-centre, randomised, double blind study. Volunteers received one single low (250 渭g) or high (500 渭g) dose of FLU-v, either alone or adjuvanted. Safety, tolerability and basic immunogenicity (IgG and IFN-纬 responses) parameters were assessed pre-vaccination and for 21 days post-vaccination.

Results

FLU-v was found to be safe and well tolerated with no vaccine associated severe adverse events. Dose-dependent IFN-纬 responses >2-fold the pre-vaccination level were detected in 80%and 100%of volunteers receiving, respectively, the low and high dose adjuvanted FLU-v formulations. No formulation tested induced any significant FLU-v antibody response.

Conclusion

FLU-v is safe and induces a vaccine-specific cellular immunity. Cellular immune responses are historically known to control and mitigate infection and illness during natural infection.